bioAffinity Technologies, Inc. - What You Need to Know

Thinking about investing in bioAffinity Technologies? The biotech world is complex. Here is a simple breakdown of what you are looking at.

1. What does this company do?

Think of bioAffinity as a company that builds "early warning systems" for lung diseases. Their main product is a test called CyPath® Lung. Instead of just looking for a tumor on an X-ray, their test examines cells in a patient’s mucus. They use a special dye that makes cancer cells "glow" under a microscope. This helps them spot lung cancer earlier than traditional methods. They also use artificial intelligence to help analyze these cell samples.

The company is in the early stages of selling its product. For the fiscal year ending December 31, 2024, bioAffinity reported about $5.4 million in revenue. This came mostly from CyPath® Lung sales and diagnostic services. However, the company still operates at a loss. They are spending heavily on research, development, and marketing to grow their market share.

2. What is happening right now? (The "Resale" Filing)

You might see news about a filing from August 2025. To be clear: this is not a new IPO. The company is not selling new shares to the public to raise money right now.

Instead, this involves "Selling Stockholders." These are investment firms and private investors who previously bought shares, preferred stock, and warrants. The company is fulfilling a legal promise to let these investors sell their shares on the open market if they choose.

Why this matters: These investors hold millions of potential shares and "warrants" (the right to buy more stock at a set price). Firms like Empery Asset Management, Alta Partners, and Intracoastal Capital are listed as holders. If these large investors sell their holdings at once, it can create "selling pressure," which often pushes the stock price down.

3. A Note on "Reporting"

You might notice that bioAffinity’s financial reports look thinner than those of giant companies. They qualify as an "Emerging Growth Company." The government allows smaller, younger companies to provide less detailed paperwork to save money. Comparing their financial reports to a massive company is like comparing a local startup to a global corporation.

4. What are the main risks?

Investing in biotech is high-risk. Key risks include:

• The "Cash Crunch": The company reports recurring losses and negative cash flow. They have stated they need to raise more money to fund operations. If they cannot generate enough revenue or find more funding, they may issue more shares. This would reduce your ownership percentage.
• "Selling Pressure": The recent filing involves a large number of shares held by institutional investors. Their potential to sell could impact the stock price.
• Nasdaq Listing Status: The company has previously received notices from Nasdaq for not meeting requirements. These include the minimum $1.00 share price and minimum equity levels. If they are delisted, the stock would move to "over-the-counter" markets. These markets typically have lower liquidity and higher price swings.
• Operational Hurdles: They run a specialized lab. Their business depends on collecting, transporting, and analyzing patient samples. Any disruption in their supply chain or a failure to maintain lab certifications could stop them from making money.

5. Who’s running the company?

CEO Maria Zannes leads the company. She has a background in business and law, which helps her navigate complex medical regulations and patents.

6. Where does it trade?

They trade on the Nasdaq stock exchange under the ticker symbol BIAF.

A Friendly Reminder: I am an AI, not a financial advisor. Biotech stocks are volatile, and prices can swing wildly. This recent filing is a reminder that early investors often sell their positions, which can affect the stock price. The company’s struggle to maintain its Nasdaq listing is a significant red flag you should research further. Never invest money you cannot afford to lose, and always check the official "Prospectus" on the SEC website before making a final decision.